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The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To
achieve this aim, it is essential to block viral replication in individuals via induction of a robust
mucosal immune response. Although it has long been recognized that inactivated poliovirus
vaccine (IPV) is incapable of inducing a strong mucosal response on its own, it has recently
become clear that IPV may boost immunity in the intestinal mucosa among individuals
previously immunized with oral poliovirus vaccine. Indeed, mucosal protection appears to be
stronger following a booster dose of IPV than oral poliovirus vaccine, especially in older
children. Here, we review the available evidence regarding the impact of IPV on mucosal
immunity, and consider the implications of this evidence for the polio eradication endgame.
We conclude that the implementation of IPV in both routine and supplementary
immunization activities has the potential to play a key role in halting poliovirus transmission,
and thereby hasten the eradication of polio.
KEYWORDS: environmental surveillance . eradication . inactivated poliovirus vaccine . mucosal immunity
. oral poliovirus vaccine . poliovirus
As we draw closer to the eradication of polio-
myelitis, the Global Polio Eradication Initia-
tive (GPEI) has outlined an endgame strategy
that includes a transition from using oral
poliovirus vaccine (OPV) to inactivated polio-
virus vaccine (IPV). To support this goal, the
WHO has recommended that all countries
introduce at least one dose of IPV into routine
immunization programs by the end of
2015 (FIGURE 1) [1]. This will be followed by the
sequential and globally synchronized removal
of the three strains of OPV, starting with sero-
type 2, until the use of OPV is halted entirely.
The need for such a transition relates to the
differing strengths and weaknesses of the two
available polio vaccines. As a live-attenuated
vaccine, OPV induces an immune response
that is virtually identical to that produced by
wild-type infection [2]. The live virus stimu-
lates both humoral immunity, which prevents
transit of poliovirus to the central nervous sys-
tem and thus protects against paralysis, and
mucosal immunity, which halts poliovirus rep-
lication at the nasopharyngeal and gastrointes-
tinal mucosal surfaces (the major entry points
of the pathogen) [3,4]. By contrast, IPV is a
killed vaccine in which the antigen dose is
administered via intramuscular injection.
Although more effective than OPV in induc-
ing a humoral immune response in low-
income countries [5,6], IPV induces only
limited mucosal immunity. In particular, it is
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less effective in preventing poliovirus replication and shedding in
the intestine. Despite being protected from paralysis, IPV-
immunized individuals may, therefore, contribute to fecal–oral
poliovirus transmission, substantially diminishing the herd effects
of immunization [7].
Since its inception in 1988, the GPEI has recommended the
use of OPV (mainly trivalent OPV [tOPV]) to protect against
all serotypes of poliovirus owing to its low cost, ease of admin-
istration, ability to produce a strong mucosal immune response
and potential to indirectly immunize secondary contacts. Fol-
lowing the elimination of wild type 2 poliovirus (one of the
three poliovirus serotypes), the GPEI developed new formula-
tions of OPV – including monovalent OPV (mOPV) in
2005 and bivalent OPV (bOPV) in 2009 – with the aim of
improving protective efficacy against the two remaining sero-
types (1 and 3) by reducing interference between the three vac-
cine strains [8,9]. These new formulations have been used in
mass campaigns (supplementary immunization activities [SIAs])
to boost population immunity in regions with persistent polio-
virus transmission. The program has achieved great success
with OPV, reducing the global number of wild poliovirus cases
by >99% since its launch. Currently, 145 countries use tOPV
to vaccinate children against polio in routine immunization
programs [10].
Although OPV has served the GPEI well, the vaccine has
certain limitations owing to its genetic instability. First, on very
rare occasions, cases of vaccine-associated paralytic poliomyelitis
(VAPP) may occur among OPV recipients or their close con-
tacts [11]. It is estimated that there are one to two cases of
VAPP per million primary immunizations with OPV [12]. Sec-
ond, vaccine polioviruses shed from OPV recipients can lose
their attenuating mutations during viral replication and can
regain transmissibility and neurovirulence [13]. In rare instances,
these vaccine-derived polioviruses (VDPVs) may circulate
widely in the population (circulating VDPVs [cVDPVs]),
showing high levels of divergence from the OPV parental
strains and transmission dynamics similar to those of wild-type
viruses [14]. Since 2000, outbreaks of cVDPV have occurred in
18 different countries, producing more than 720 cases of polio-
myelitis [13]. Serotype 2 has caused more than 85% of these
cases, which may be attributed to deficits in population immu-
nity to type 2 poliovirus following the replacement of tOPV
with mOPV and bOPV targeting serotypes 1 and 3 in SIAs
since 2005 [15].
A major concern with transitioning from OPV to IPV is the
limited intestinal mucosal immunity provided by the latter. By
failing to halt poliovirus replication in the gut mucosa, the use
of IPV may enable fecal–oral transmission to continue – a sce-
nario at odds with the eradication endgame. However, recent
evidence has called into question the traditional view that IPV
offers limited mucosal protection by showing that administer-
ing the vaccine to individuals who have previously received
OPV and are ‘mucosally primed’ significantly boosts mucosal
immunity [16,17].
Introduced† to date (87 countries or 45%)
0 1250 2500 5000
Kilometers
Formal commitment to introduce in 2015 (103 countries or 53%)
Not applicableIntend to introduce in 2015 (4 countries or 2%)
(Cook Islands, Fiji, Mauritius, Thailand)
†Includes introductions in some parts of the country only
Figure 1. Map of global inactivated poliovirus vaccine use and planned dates for its introduction. Data source: WHO/IVB
Database, as of 1 May 2015. Map production: Immunization Vaccines and Biologicals (IVB), WHO.
Reproduced with permission from [73].
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Given the risk of VAPP and cVDPVs, the use of OPV must
be phased out from all immunization activities if the eradication
of polio is to be achieved [1]. To fill the gap in poliovirus immu-
nity, IPV must first be introduced into routine immunization
activities globally. However, the extent to which IPV can fill the
role of its live counterpart remains to be seen. A delicate balance
between the two vaccines must be achieved to eliminate wild
polioviruses and prevent cVDPVs. The impact of IPV on
mucosal immunity is key to this balance. In this review, we
examine the available evidence regarding the influence of IPV
on mucosal protection. In doing so, we address the potentially
vital role that IPV may play in halting viral transmission during
the polio eradication endgame.
Measuring mucosal immunity to poliovirus
When considering vaccine-induced protection against poliomy-
elitis, the distinction between humoral and mucosal immunity
is crucial. Humoral immunity refers to the presence of
poliovirus-specific neutralizing antibodies in blood (predomi-
nantly IgG) and can be measured using a standardized micro-
neutralization assay [18]. Administration of antibody has been
shown to protect against poliomyelitis and the detection of
antibodies at a titer of 1 in 8 or greater is considered a good
correlate of protection [19]. However, immunity at mucosal sur-
faces – in particular, the nasopharyngeal and intestinal mucosae,
which form the two primary sites of poliovirus replication – is
required to prevent viral replication and shedding, and thus
halt transmission. In this review, we refer to mucosal immunity
as the degree of protection against poliovirus replication at these
surfaces. The immune mechanisms responsible for this protec-
tion may involve both mucosally targeted IgA responses and
transudation of serum antibodies.
The most widely adopted measure of poliovirus-specific
mucosal protection involves administration of a challenge dose
of OPV. The shedding of vaccine polioviruses in nasopharyngeal
and stool samples collected after challenge signifies viral replica-
tion in the nasopharynx and gut, respectively, while the absence
of shedding can be viewed as an indicator of mucosal protection.
During the early stages of poliomyelitis control, both oral–oral
and fecal–oral transmission were thought to be common. Com-
munity transmission was ascribed to the former and familial
transmission to the latter [20]. Today, fecal–oral transmission is
thought to predominate in countries at risk of poliomyelitis.
Our main focus here is therefore on fecal shedding. Outcomes
of challenge studies may include one or more of the following:
the proportion of individuals who shed OPV, the duration of
viral shedding and the titer of shedding. Typically, a full or par-
tial dose of OPV is administered as challenge. However, the
degree to which this approach accurately reflects natural poliovi-
rus exposure (at a significantly lower dose) is uncertain.
Alternative assays for mucosal immunity include the measure-
ment of poliovirus-specific antibody in the nasopharynx, saliva or
feces. This has been achieved using a variety of methods, of
which the two most common are ELISA for poliovirus-specific
IgA [21,22] and neutralization assays [21,23,24]. Although higher titers
of nasal IgA have been linked with lower quantities and shorter
duration of nasopharyngeal shedding after OPV challenge [25],
other studies have not found such correlations [3] and the level of
secretory antibody required for protection against poliovirus rep-
lication is unknown. Moreover, unlike the microneutralization
assay for serum antibodies, a standardized approach for detecting
secretory poliovirus-specific antibodies has not been widely
adopted, making it difficult to compare findings among studies.
Other potential indicators of mucosal immunity include the pres-
ence of circulating poliovirus-specific IgA- and IgG-producing
cells expressing gut-homing markers (such as a4b7 integrin),
which may be examined via fluorescence-activated cell sorting
and enzyme-linked immunosorbent spot assay [22]. Again, the
relationship between these circulating cells and mucosal protec-
tion against poliovirus remains uncertain. Response to OPV chal-
lenge is, therefore, viewed as the gold standard for measuring
mucosal immunity to poliovirus.
When considering any of the measures above, it is apparent
that OPV is capable of inducing a strong mucosal immune
response. OPV-immunized individuals typically begin to secrete
IgA in the nasopharynx and duodenum 1–3 weeks after vaccine
administration [23]. This provides a strong barrier to poliovirus
re-infection: in one of the earliest challenge studies, Ghendon
and Sanakoyeva observed shedding after mOPV
type 1 challenge in 37% of individuals previously vaccinated
with three doses of mOPV (in the order type 1, type 3,
type 2), with a mean shedding duration of 5 days and a mean
viral titer of 150 median tissue culture infectious doses per
gram of stool (results similar to those observed after exposure
to wild type 1 poliovirus) [2]. By contrast, shedding was docu-
mented in 80% of seronegative unvaccinated individuals, with
a mean duration of >20 days and a mean viral titer of
141,000 median tissue culture infectious doses per gram. The
mucosal protection afforded by OPV has been confirmed by
many studies since (reviewed in [26]). However, the duration of
this immunity remains equivocal: Grassly et al. documented
significant waning of mucosal protection within 1 year of OPV
administration among Indian infants [27].
Impact of IPV on mucosal immunity
IPV-only schedules
When administered to naı¨ve individuals, IPV does not induce
a classic, class-switched, mucosally targeted IgA response [28]. It
has repeatedly been shown that children given IPV without
prior exposure to OPV remain susceptible to intestinal poliovi-
rus infection (e.g., [29,30]). In a recent meta-analysis, Hird and
Grassly found no significant difference in the odds of viral
shedding following OPV challenge among IPV-immunized
compared with unvaccinated individuals [26]. By contrast, the
odds of shedding were significantly reduced among OPV-
immunized individuals, both in comparison to unvaccinated
and IPV-immunized individuals.
Although IPV does not protect against poliovirus replication
in the intestine, several challenge studies have documented a
reduction in the duration and/or titer of viral shedding in IPV-
Impact of inactivated poliovirus vaccine on mucosal immunity Review
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immunized individuals [2,30–34], albeit to a much lesser extent
than in OPV-immunized individuals [2,3,32]. In the challenge
study described above, Ghendon and Sanakoyeva observed
shedding after OPV challenge in 74% of individuals immu-
nized with two doses of IPV, with a mean shedding duration
of 12.3 days and a mean viral titer of 13,000 median tissue
culture infectious doses per gram of stool (a 10-fold decrease in
mean titer compared with unvaccinated individuals) [2]. IPV
has also been shown to prevent shedding in the nasopharynx
upon either natural exposure to wild virus [20,29,35] or challenge
with OPV [33,36,37]. However, evidence to support nasopharyn-
geal protection remains limited to a small number of studies
with few subjects. Higher serum antibody titers following IPV
administration have been linked with increased protection
against shedding in both the intestine [32,33] and nasophar-
ynx [20,33], although Onorato et al. [3] found no evidence for
this trend. Since the majority of these studies were carried out
in settings either endemic for poliovirus or concurrently using
OPV, prior exposure to live poliovirus and consequent mucosal
priming cannot be ruled out. However, the findings suggest
that administration of IPV alone may, at least partially, limit
the duration and titer of virus excretion in the nasopharynx
and intestine following subsequent poliovirus exposure.
Studies of secretory antibodies following IPV administration
are generally consistent with the results of challenge studies.
Several trials have documented poliovirus-specific IgA [3,21,24]
and neutralizing antibodies [21,24] in nasopharyngeal secretions
among individuals immunized with enhanced-potency IPV, in
some instances at titers comparable to those induced by
OPV [3]. However, prior exposure to circulating wild-type or
vaccine polioviruses cannot be ruled out in these studies, and
Herremans et al. [22] observed no IgA in saliva or stool among
14 IPV-immunized adults from the Netherlands, where prior
exposure to OPV or wild virus would be limited. The same
group also observed no IgA in the serum of 104 children
4 months after they received their sixth dose of IPV [28].
Onorato et al. documented similar titers of poliovirus-specific
IgA in stool samples obtained from infants previously immu-
nized with OPV or IPV; however, significantly fewer OPV
than IPV recipients shed poliovirus after challenge [3]. Notably,
fecal IgA titers in OPV recipients correlated with protection
against viral shedding in stool, while the same was not true for
IPV recipients. These findings may relate to differences in the
specificity of secretory antibodies induced by the two vaccines,
with OPV having been shown to promote a more potent anti-
body response against poliovirus antigens that have been treated
with trypsin (simulating the enzymatic modifications that occur
during gastrointestinal transit) [21]. Other mechanisms may also
be involved in poliovirus-specific immunity at mucosal sites; in
particular, it has been suggested that the reduction in duration
and titer of viral shedding following OPV challenge in IPV-
immunized individuals may be caused, in part, by transudation
of serum IgG rather than the induction of IgA-secreting cells at
the mucosal surface [38]. However, the extent of this effect
remains uncertain.
Despite the absence of strong mucosal immunity following
IPV administration, several industrialized countries – including
Sweden, Finland, Iceland and the Netherlands – implemented
IPV-only schedules in their routine immunization programs in
the late 1950s and subsequently eliminated polio [39]. These
countries have never or only occasionally used OPV. The suc-
cess of IPV-only schedules in these regions has been attributed
to their high standards of hygiene and sanitation, which may
limit fecal–oral transmission in favor of pharyngeal spread. In
such conditions, a reduction in the titer and duration of polio-
virus shedding in the nasopharynx among IPV recipients may
be sufficient to eliminate viral circulation.
It is unlikely, however, that IPV-only schedules would be
sufficient to halt poliovirus transmission in settings where
fecal–oral transmission predominates. This has been highlighted
on several occasions by poliovirus importations into polio-free
countries using IPV-only schedules. The most recent example
is Israel, which was certified as polio-free in June 2002 and
implemented an IPV-only schedule from 2005 onward. Despite
high routine immunization coverage (estimated at approxi-
mately 95% in 2012), wild type 1 poliovirus was detected in
sewage samples collected in southern Israel between February
and July 2013, and subsequent surveillance indicated country-
wide spread of the virus [40,41]. This has been attributed to the
lack of intestinal mucosal immunity in cohorts of children
born after OPV withdrawal who were exclusively immunized
with IPV [40,41]. No cases of acute flaccid paralysis were
detected, probably owing to the high population immunity
against paralysis induced by IPV immunization. Notably, con-
trol of the outbreak was achieved through the re-introduction
of OPV in routine and campaign-based immunization activi-
ties, and OPV is once again part of the routine immunization
schedule in Israel (together with IPV).
IPV/OPV mixed schedules
In contrast to IPV-only schedules, the impact of IPV on muco-
sal immunity when administered alongside OPV in mixed vac-
cination schedules remains equivocal. Recently, two clinical
trials conducted in India demonstrated that IPV has the poten-
tial to significantly boost mucosal protection in children previ-
ously immunized with OPV. John et al. compared viral
excretion following a challenge dose of bOPV among children
1–4 years of age who had received either one dose of IPV, one
dose of bOPV, or no vaccine 4 weeks earlier [17]. The propor-
tion of individuals shedding vaccine polioviruses after bOPV
challenge was significantly lower among IPV recipients (12 and
8% for serotypes 1 and 3, respectively) compared with those
who had received no vaccine (19 and 26% for serotypes 1 and
3, respectively). By contrast, no significant reduction in the
proportion of shedders was observed among individuals who
received bOPV.
A similar approach was adopted by Jafari et al., who admin-
istered either one dose of IPV, one dose of bOPV, or no vac-
cine to children aged 6–11 months, 5 years or 10 years and
compared subsequent response to a challenge dose of
Review Parker, Molodecky, Pons-Salort, O’Reilly & Grassly
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bOPV [16]. Prior to enrollment, the children would have
received OPV during routine immunization and SIAs. Again,
delivery of IPV significantly reduced the proportion of subjects
excreting virus after challenge. The reduction in shedding was
greatest at 10 years of age and was significantly greater in IPV
than OPV recipients in all age groups. These results suggest
not only that IPV has the potential to significantly boost
mucosal immunity in OPV-primed children but also that this
boosting effect may exceed that of an additional dose of OPV.
By targeting children aged >6 months, the trials by John
et al. [17] and Jafari et al. [16] best capture the potential impact
of introducing IPV in SIAs (which target all children up to
5 years of age).
The results of these studies have helped to clarify the impact
of IPV on mucosal immunity; the boosting effect of IPV in
OPV-primed individuals has previously been explored with
inconclusive findings. Herremans et al. compared poliovirus-
specific IgA response after administration of IPV among adults
previously exposed to either IPV or OPV and observed a boost
in mucosal (salivary) IgA response only among individuals pre-
viously immunized with OPV [22]. Administration of IPV also
induced circulating IgA-producing cells in OPV-primed but
not in IPV-primed volunteers. By contrast, studies by Parent
du Chatelet et al. [42] and the WHO [43] compared response to
a challenge dose of mOPV among infants immunized either
with OPV-only schedules or a mixed schedule involving admin-
istration of up to three doses of IPV to OPV-primed infants at
timings consistent with routine immunization. No significant
difference in the proportion of individuals shedding after chal-
lenge was observed in either study. The failure to find a muco-
sal boosting effect of IPV in these studies may be due to the
low proportion of subjects excreting virus (range 0.5–8.6% and
4–13%, respectively), limiting the potential to detect significant
differences between groups. Another study performed in Oman
compared response to a challenge dose of type 3 mOPV at
15 months of age among infants who had received either IPV,
tOPV or type 3 mOPV at 9 months (along with five preceding
doses of OPV) [44]. No significant differences were observed
between the groups, but once again the proportion of individu-
als shedding the challenge virus was low (13% overall). The
proportion of children excreting the challenge virus in the
recent studies from India was considerably higher, which is
likely due to differing immune profiles in these study popula-
tions, the inclusion of older children and the lapse in time since
these children were last vaccinated with OPV. Older age groups
may be more susceptible to poliovirus re-infection owing to the
waning of OPV-induced mucosal immunity [27]. Thus, while
concomitant or recent OPV administration may mask the bene-
ficial impact of IPV on mucosal immunity, the boosting effect
of IPV may be more apparent when OPV-induced mucosal
protection has waned. Overall, the findings suggest that the use
of IPV in SIAs will provide a significant boost in mucosal
immunity, while the presence of a boosting effect during rou-
tine immunization has yet to be confirmed. TABLE 1 provides a
summary of the overall impact of OPV and IPV on humoral
and mucosal immunity, and on the risk of VAPP and
type 2 cVDPV emergence (the serotype of greatest concern
ahead of the upcoming withdrawal of type 2 OPV). Notably,
the precise effects of the vaccines will depend on whether they
are being used in routine or supplementary immunization
efforts and on the vaccination history of the recipients.
Although mechanisms by which IPV may boost mucosal
immunity remain unclear, prior exposure to live poliovirus
appears to be a requirement. Several studies have examined the
impact of mixed vaccination schedules in which IPV was
administered prior to OPV and observed no significant impact
of IPV on mucosal protection, as measured either by a chal-
lenge dose of OPV [45] or nasopharyngeal IgA response [24,38].
Thus, prior exposure to IPV does not appear to alter the
mucosal immunity induced by OPV. The immunological path-
way for the boosting effect of IPV in OPV-primed individuals
may rely on activation of memory cells formed after exposure
to the live virus (i.e., OPV). Dendritic cells located in the gut
mucosa have been shown to promote the gut-homing receptor
a4b7 integrin on activated B and T cells, whereas this marker
is not induced by dendritic cells isolated from the spleen [46].
Herremans et al. observed that a large percentage of circulating
IgA-producing cells induced following administration of IPV to
OPV-immunized adults expressed a4b7 integrin [22]. Accord-
ingly, the authors concluded that presentation of antigens from
IPV at peripheral lymph nodes may induce the proliferation of
memory cells formed after OPV exposure, resulting in a circu-
lating population of IgA-producing cells expressing gut-homing
receptors. IPV has also been shown to induce an increase in
poliovirus-specific CD4+ T cells expressing a4b7 in adults pre-
viously immunized with OPV [47], while a boost in secretory
IgA response was observed following administration of IPV to
individuals previously exposed to wild-type poliovirus [48].
FIGURE 2 illustrates the different effects of IPV boosting in indi-
viduals previously immunized with OPV or IPV, based on the
findings reported above.
IPV in the polio eradication endgame
There are two contexts in which IPV will be used as the GPEI
seeks to secure the eradication of polio: routine immunization
and SIAs. In each of these settings, the potential boosting of
protection against intestinal poliovirus replication among OPV-
immunized children has significant benefits for the eradication
endgame, as discussed below.
IPV in routine immunization
The WHO now recommends that all countries introduce at
least one dose of IPV in routine immunization [1], a measure
primarily motivated by the need to provide adequate poliovirus-
specific immunity by alternative means prior to OPV with-
drawal. In countries presently immunizing infants with OPV at
6, 10 and 14 weeks of age and opting to introduce one dose of
IPV, it is recommended that this dose be co-administered with
OPV at 14 weeks of age. This strategy avoids the need for addi-
tional vaccination visits. Moreover, by administering IPV later
Impact of inactivated poliovirus vaccine on mucosal immunity Review
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in infancy, interference by maternal antibodies will be dimin-
ished, thus improving immunogenicity [43,49–51]. An additional
benefit of introducing IPV in routine immunization may be a
boosting of the mucosal immune response induced by preceding
OPV doses. To date, this boosting effect has been demonstrated
only among older children (>6 months of age) [16,17], while
observations from younger infants remain equivocal [42,43]. How-
ever, it is possible that a similar boosting of mucosal immunity
may occur in early infancy, either in the strength or duration of
protection. Several ongoing trials may help to clarify this possi-
bility. In particular, studies currently underway in Latin Amer-
ica (ClinicalTrials.gov identifier NCT01831050) and Pakistan
(NCT02189811) will assess the impact of mixed OPV/IPV
administration (according to the schedule outlined above) on
the response to OPV challenge.
In countries presently immunizing infants with OPV at 2,
4 and 6 months of age, the WHO recommends that IPV be co-
administered at either 4 or 6 months of age. Again, the admin-
istration of IPV to OPV-primed infants in this schedule may
enhance mucosal immunity, although such an effect has yet to
be demonstrated. An alternative strategy being investigated by a
trial in Chile (NCT01841671) is to immunize infants with IPV
prior to OPV during routine immunization. This strategy may
reduce the risk of VAPP, which is highest at the first exposure
to OPV. However, it is unlikely that the IPV dose(s) will have
any significant beneficial effects on mucosal immunity owing to
the lack of prior live virus exposure in such a schedule. In ideal
circumstances, a routine immunization schedule of IPV–OPV–
IPV, or IPV followed by co-administration of IPV and OPV at
subsequent visits, might minimize the risk of VAPP while maxi-
mizing humoral and mucosal protection. The WHO recom-
mendation is that ‘at least one dose of IPV’ should be
introduced in countries currently relying solely on OPV in
advance of the withdrawal of serotype 2 OPV [1]. Financial con-
straints mean that most countries will introduce just a single
IPV dose, although this may be a prelude to adoption of a
more extensive IPV schedule in routine programs in the future,
perhaps through the use of combination products.
A major challenge with the planned introduction of IPV is
the persistently low routine immunization coverage in many
countries either endemic for polio or at high risk of virus
importation. Coverage at 14 weeks of age has been identified as
a particular problem owing to dropout across sequential routine
vaccination visits [52], which poses a challenge to the proposed
introduction of IPV at this dose. High-risk countries typically
administer tOPV in routine immunization and rely heavily on
SIAs (mainly using bOPV) to improve coverage, leaving large
populations vulnerable to type 2 poliovirus. These countries
Table 1. Effects of different vaccination strategies on humoral and mucosal immunity to poliovirus types 1,
2 and 3, and the risk of vaccine-associated paralytic poliomyelitis and type 2 circulating vaccine-derived
poliovirus emergence.
Humoral immunity Mucosal immunity VAPP risk Risk of type 2
cVDPV emergence†
PV1 PV2 PV3 PV1 PV2 PV3
Routine immunization
IPV–IPV–IPV +++ +++ +++ – – – – –
tOPV–tOPV–tOPV +++ +++ +++ +++ +++ +++ + +
bOPV–bOPV–bOPV +++ ?‡ +++ +++ ?‡ +++ + –
tOPV–tOPV–tOPV+IPV +++ +++ +++ +++ +++ +++ + +
IPV–tOPV–tOPV +++ +++ +++ +++ +++ +++ – +
bOPV–bOPV–bOPV+IPV +++ ?‡ +++ +++ ?‡ +++ + –
IPV–bOPV–bOPV +++ ?‡ +++ +++ ?‡ +++ – –
Supplementary immunization activities
tOPV +++ +++ +++ +++ +++ +++ + +
bOPV +++ ?‡ +++ +++ ?‡ +++ + –
IPV (low tOPV routine
immunization coverage)
+++ +++ +++ + + + – –
IPV (high tOPV routine
immunization coverage)
+++ +++ +++ +++ +++ +++ – –
–: Absent or negligible; +: Low; ++: Moderate; +++: Strong; bOPV: Bivalent oral poliovirus vaccine; cVDPV: Circulating vaccine-derived poliovirus; IPV: Inactivated poliovi-
rus vaccine; PV1: Type 1 poliovirus; PV2: Type 2 poliovirus; PV3: Type 3 poliovirus; tOPV: Trivalent oral poliovirus vaccine; VAPP: Vaccine-associated paralytic poliomyelitis.
†Refers to the likelihood of a Sabin type 2 virus regaining neurovirulence and transmissibility. Any vaccination strategy involving the administration of type 2 Sabin strains
(such as those including tOPV) will carry a risk of type 2 cVDPV emergence.
‡There may be some heterotypic immunity among the poliovirus strains. The extent of this immunity remains equivocal, but is likely to be short-lived and of limited
significance [55–57].
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have also experienced repeated type 2
cVDPV emergences and prolonged out-
breaks [53,54]. A primary focus of the GPEI
strategic plan is to strengthen routine
immunization, so as to ensure adequate
protection against type 2 poliovirus in the
form of both humoral and mucosal immu-
nity prior to the switch from tOPV to
bOPV (accompanying the withdrawal of
serotype 2 OPV). There may be some pro-
tection against type 2 virus in populations
given bOPV due to heterotypic immunity
(TABLE 1); specifically, antibodies induced by
poliovirus types 1 and/or 3 may have some
degree of cross-reactivity with epitopes on
type 2 poliovirus [55,56]. However, hetero-
typic protection against shedding and
poliomyelitis is likely to be short-lived and
of limited significance [57].
IPV in SIAs
Wide-scale and frequent SIAs targeting chil-
dren under 5 years of age have been rolled
out to compensate for low routine immuni-
zation coverage in infected countries. In
Pakistan and Nigeria, in particular, there has been a heavy reliance
on SIAs. Traditionally, tOPV has been used in SIAs; however, the
transition to mOPVs and bOPVs targeting serotypes 1 and 3 in
recent years has taken place in endemic and high-risk countries to
target these remaining wild virus serotypes. To compensate for
the limited use of type 2 OPV in these countries and to boost
mucosal immunity to serotypes 1 and 3, IPV has recently been
used alongside bOPV in parts of Kenya, Nigeria and Pakistan.
The introduction of IPV into SIAs poses particular challenges: in
addition to the increased costs of the vaccine, the campaigns
require extra training for healthcare workers, are limited to fixed
health posts because of the challenges in administering the vaccine
through house-to-house visits and require more intensive social
mobilization efforts to promote acceptance of the vaccine. Despite
these challenges, SIAs involving IPV to date have achieved high
coverage and good acceptance [58], leading the GPEI to plan fur-
ther IPV SIAs in high-risk areas of Pakistan, Afghanistan and
Nigeria in 2015. In light of the potential boosting of mucosal
protection among OPV-primed children [16,17], the introduction
of IPV into SIAs may contribute to the reduction in viral trans-
mission which is required to halt poliovirus circulation in
endemic regions. To date, the boosting effect of IPV on mucosal
immunity has been demonstrated only among individuals
enrolled in clinical trials. With appropriate surveillance, the use of
IPV in SIAs may enable the population-level impacts of this
boosting effect on poliovirus transmission to be determined.
IPV may also play an important role in boosting mucosal
immunity to type 2 poliovirus prior to the withdrawal of sero-
type 2 OPV (currently planned for 2016). To minimize the
risk of type 2 cVDPV emergence, several tOPV campaigns will
likely be conducted prior to the synchronized withdrawal of
type 2 OPV. Including IPV alongside OPV in these supple-
mentary campaigns may have a greater boosting effect on
mucosal immunity compared to OPV alone, thereby decreasing
the likelihood of a type 2 VDPV emerging and spreading fol-
lowing the final doses of tOPV. A major challenge, however,
will be the supply of sufficient quantities of IPV, most likely
limiting IPV use to key high-risk areas.
Environmental surveillance
Following the globally coordinated withdrawal of OPV (starting
with serotype 2) [1], IPV will be the only poliovirus vaccine in
use. At this point, the beneficial boosting effects of IPV on muco-
sal immunity will be lost, leading to an increased risk of silent
transmission of wild polioviruses or cVDPVs. The recent observa-
tion of silent poliovirus circulation in Israel emphasizes the
importance of environmental surveillance in detecting viral trans-
mission within populations immunized with IPV alone. This will
be of particular importance in countries with poor standards of
hygiene and sanitation, where there is greater potential for fecal–
oral transmission. Currently, fewer than 30 countries systemati-
cally report the results of environmental surveillance to the GPEI.
The expansion of this surveillance system will be necessary to help
establish that wild poliovirus transmission has been brought to a
halt after the cessation of paralytic cases and, subsequently, to
monitor for vaccine virus circulation after OPV withdrawal [1,59].
Response to the detection of wild polioviruses or cVDPVs may
involve the temporary re-introduction of OPV in the affected
regions. However, the appropriate scale of such a response is
unclear, and represents an important topic of current research.
Primary
immunization IPV boost
Serum IgG
Nasopharyngeal/
intestinal IgA
Nasopharyngeal/
intestinal IgA0 1 2
Weeks after immunization Weeks after immunization
3 4 5 6 0 1 2 3 4 5 6Waning
A
nt
ib
od
y 
tit
er
IPV prime, IPV boost
OPV prime, IPV boost
Figure 2. Schematic representation of serum and secretory antibody responses
following administration of IPV to OPV- or IPV-primed individuals. Primary immu-
nization with OPV induces both a humoral response (serum IgG) and a mucosal response
(intestinal and nasopharyngeal IgA), whereas IPV induces only a humoral response and
potentially a limited mucosal response in the nasopharynx. However, following the wan-
ing of OPV-induced mucosal immunity, administration of IPV is capable of boosting both
humoral and mucosal immunity in OPV-primed individuals. The same boosting of
humoral immunity does not occur among individuals without prior OPV exposure.
IPV: Inactivated poliovirus vaccine; OPV: Oral poliovirus vaccine.
Informed by [16,17,22,23].
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Alternative IPV formulations
Currently, the cost of full-dose intramuscular IPV for Gavi-
supported countries is nearly seven-times that of tOPV
(US$0.15 for tOPV and US$1 for IPV) [60,61], posing an
immense challenge to the financial feasibility of wide-scale
introduction. Also, the time required for manufacturers to
expand their IPV production capacity will likely exceed the
immediate demand for the vaccine, limiting its use in SIAs, par-
ticularly in the period preceding type 2 OPV withdrawal.
Numerous cost- and antigen-reduction strategies for the short to
medium term are therefore being explored, and these strategies
may impact the boosting effect of IPV on mucosal immunity.
One option to reduce the cost and meet the rapid increase in
demand is to administer fractional (1/5) doses of IPV intrader-
mally. The use of fractional IPV (fIPV) as a substitute for full-
dose IPV would reduce the amount of antigen required, thereby
increasing the number of available doses and reducing the cost
per vaccination. Evidence regarding the immunogenicity of fIPV
is inconclusive: while several studies have demonstrated that fIPV
induces similar seroconversion rates to full-dose vaccine [62–64],
others have found that fIPV induces significantly lower serocon-
version rates [50,65,66], and antibody titers have generally been
found to be lower following fIPV compared with full-dose
IPV [50,64]. Data regarding the impact of fIPV on mucosal immu-
nity are currently limited. However, Mohammed et al. observed
shedding in a significantly greater proportion of children who
had received three intradermal doses of fIPV compared with
recipients of three full intramuscular doses of IPV following
type 1 mOPV challenge [64]. Further evaluation of both humoral
and mucosal immunogenicity following receipt of fIPV is
required to determine whether this vaccine is able to provide ade-
quate population protection in the polio eradication endgame.
Alternative approaches include the development of IPV from
attenuated Sabin strains or further attenuated polioviruses. The
switch to Sabin IPV (sIPV) would eliminate the large volumes
of wild polioviruses generated during traditional IPV produc-
tion, thereby enabling the safe production of IPV in developing
countries [67]. sIPV demonstrated comparable immunogenicity
to conventional IPV (i.e., Salk IPV) in a randomized, con-
trolled dose-escalation trial carried out in Poland [68], and pro-
duction of the first sIPV was approved in China in January
2015. However, whether sIPV produces a similar mucosal
boosting effect to Salk IPV is yet to be determined. Other
strategies being explored include the addition of mucosal adju-
vants to IPV with the aim of improving intestinal response to
the vaccine [69] and the development of stable Sabin strains that
are less likely to regain neurovirulence [70].
In the longer term, many countries may choose to incorpo-
rate IPV into routine immunization schedules within combina-
tion vaccines (a strategy currently adopted in many high-
income countries). Although several existing vaccines combine
IPV, diphtheria, acellular pertussis, tetanus, Haemophilus influ-
enzae type B and (in some cases) hepatitis B antigens, efforts
are underway to develop hexavalent vaccines that include both
IPV and whole-cell pertussis (wP) [71]. wP vaccines are cheaper
to produce than acellular pertussis vaccines, and are therefore
the preferred formulation in many low-income countries. How-
ever, alternative methods of wP inactivation will be required
for vaccines combining wP alongside IPV, as thimerosol (which
is currently used to inactivate wP) has been shown to negatively
impact IPV potency [72]. The potential impact of these combi-
nation vaccines on poliovirus-specific mucosal immunity will
be an important consideration, particularly if they enter the
market prior to OPV cessation.
Expert commentary
IPV is playing a key role in the eradication of polio, and its
potential influence on mucosal immunity may well be crucial
to the success of the eradication endgame. While previously
thought to have only a minimal influence on mucosal immu-
nity, it is now recognized that IPV significantly boosts the
mucosal protection of individuals whose primary response to
OPV has waned. Moreover, this effect may exceed the protec-
tion conferred by additional doses of OPV. Although the sig-
nificant boosting effect of IPV has currently been demonstrated
only in children aged >6 months, the incorporation of at least
one dose of IPV in routine immunization programs (as recom-
mended by the WHO) may enhance protection against subse-
quent intestinal infection. Where resources permit, there is also
a strong rationale for using IPV alongside OPV in SIAs (as
currently being carried out in high-risk endemic areas); it is
likely that doing so will have a greater effect on both humoral
and mucosal protection than the use of OPV alone.
Five-year view
The transition from OPV to IPV poses a complex set of
challenges for the GPEI. In this review, we have focused on the
impact of IPV on mucosal immunity and the implications of
this for the polio eradication endgame. Other important
considerations include how best to recognize and respond to
type 2 cVDPV emergence at the time of and after withdrawal
of serotype 2 OPV. Following withdrawal, an increasing cohort
of newborns will lack intestinal immunity to type 2 poliovirus,
and may also have incomplete humoral protection owing to
gaps in routine coverage, putting them at risk of paralytic
poliomyelitis from residual circulation of type 2 cVDPV.
Similar issues will also be encountered during the subsequent
withdrawal of OPV serotypes 1 and 3. In the meantime,
several ongoing trials may shed further light on the impact of
IPV on mucosal immunity, the degree of cross-immunity
induced by OPV, and the potential value of alternative vaccine
formulations, including fIPV and sIPV. In preparation for
the introduction of IPV, there will be a continuing emphasis
on strengthening routine immunization systems, particularly
in high-risk areas. Finally, given that IPV alone is insufficient
to prevent the silent transmission of wild-type or vaccine-
derived polioviruses, heightened environmental surveillance and
clear response planning will be necessary to identify and
halt poliovirus transmission following the planned withdrawal
of OPV.
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Key issues
. The induction of robust mucosal immunity is necessary to halt poliovirus transmission, and is therefore crucial to the success of the
polio eradication endgame.
. Inactivated poliovirus vaccine (IPV) has long been thought to induce only limited mucosal immunity; however, it has recently been
shown that the vaccine may significantly boost mucosal protection among individuals who have previously received oral poliovirus vac-
cine (OPV). This effect may exceed the boost in mucosal immunity induced by additional doses of OPV.
. It is now recommended that at least one dose of IPV be included in all routine immunization programs, and the vaccine will also
increasingly be used alongside OPV in supplementary immunization activities conducted in polio-endemic countries. In both these con-
texts, the boosting of mucosal immunity by IPV may help eliminate poliovirus transmission.
. Following OPV withdrawal, environmental surveillance will be crucial for the detection of poliovirus circulation, owing to the potential
for silent poliovirus circulation in populations immunized only with IPV.
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